" class="no-js "lang="en-US"> MediCardia Health Inc. Integrates Optimize EP C-aRM to Develop First of it's Kind, Comprehensive Connected Cardiac Care Platform - Medtech Alert
Sunday, April 21, 2024

MediCardia Health Inc. Integrates Optimize EP C-aRM to Develop First of it’s Kind, Comprehensive Connected Cardiac Care Platform

MediCardia Health Inc., a pioneer in global digital health, announced today that the Company has completed integration with Optimize EP‘s CaRM CIED (cardiovascular implantable electronic device) platform. The combined platform will comprise the worlds 1st comprehensive connected cardiac care platform for management of patients chronic cardiovascular conditions and cardiac implanted devices. As a partner, Optimize EP will provide comprehensive CIED data to support the MediCardia Virtuas remote and virtual care platform. Both companies have agreed to comarket and co-sell their products as a single platform.

“We believe in the 3P’s of medicine—predictive, preventive, and personalized—and it motivates us every day to gain deeper cardiology and AI expertise and create smarter technical solutions,” said Ravi Kartan, President, and CEO of Optimize EP. “MediCardia’s in-depth experience makes them an ideal partner for Optimize EP. Together we are developing applications that will promote long and healthy life.”

With the integration of comprehensive CIED data, MediCardia Health continues to lead the industry in cardiovascular data interoperability and visualization. Providers can view multiple data streams across workflows simultaneously, including:

  • Remote patient monitoring (RPM) of vital signs
  • Chronic care management
  • Principal Care Management
  • CIED data management with the OptimizeEP C-aRM integration

“Leveraging EMR integration, data typically trapped in unstructured text is discretized using Natural Language Processing and Machine Learning technologies. This ‘context’ enables correlations to be made instantly and effectively, shortening time to diagnosis and provider action” said Indrajit Choudhuri, M.D., CEO of MediCardia Health.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more